Researchers have developed a new fluorescent probe that detects elevated levels of a protein called LAP, which indicates atherosclerosis and heart disease risk. According to Gram Research analysis, this probe successfully identified the disease in laboratory cells, living mice, and human blood samples, with particularly high LAP levels in patients with severe arterial narrowing exceeding 60%. While still in development, this breakthrough could eventually enable earlier heart disease detection through a simple blood test.
Scientists have created a special fluorescent probe that glows when it detects a protein called LAP, which is elevated in people with atherosclerosis—a condition where arteries become clogged with plaque. According to Gram Research analysis, this new tool successfully identified atherosclerosis in both laboratory foam cells and living mice with the disease. When tested on human blood samples, the probe found significantly higher LAP levels in patients with severe arterial narrowing compared to healthy individuals. This breakthrough could eventually help doctors diagnose heart disease risk earlier and more accurately, potentially saving lives through earlier intervention.
Key Statistics
A 2026 research study published in Spectrochimica Acta demonstrated that a fluorescent LAP probe successfully distinguished atherosclerotic foam cells from normal macrophages in laboratory settings, with a strong linear correlation between fluorescence intensity and LAP concentration.
According to 2026 research reviewed by Gram, serum LAP activity was significantly elevated in atherosclerotic mice and in human patients with arterial stenosis, particularly in those with severe stenosis exceeding 60%, as confirmed by receiver operating characteristic curve analysis.
A 2026 study found that the LAP fluorescent probe exhibited low toxicity with no observable organ damage in animal models, suggesting potential safety for future clinical diagnostic applications in atherosclerosis detection.
The Quick Take
- What they studied: Whether a new glowing probe that detects a specific protein (LAP) could help identify atherosclerosis, the buildup of plaque in arteries that leads to heart disease.
- Who participated: Laboratory experiments with mouse cells and mice fed a high-fat diet to mimic heart disease, plus blood samples from human patients with varying degrees of arterial narrowing.
- Key finding: The LAP probe successfully detected elevated protein levels in atherosclerotic mice and in human patients with severe arterial blockages (over 60% narrowing), with a strong correlation between protein levels and disease severity.
- What it means for you: This research suggests a potential new diagnostic tool that could help doctors identify heart disease risk earlier through a simple blood test, though it’s still in development and not yet available for routine clinical use.
The Research Details
Researchers created a special fluorescent molecule designed to light up when it encounters a protein called leucine aminopeptidase (LAP), which is produced in higher amounts during atherosclerosis. They built this probe using a chemical scaffold called hemicyanine and attached a peptide sequence that LAP recognizes, similar to how a lock recognizes a specific key.
The team first tested their probe in laboratory settings using foam cells (immune cells filled with cholesterol that are hallmarks of atherosclerosis) and compared them to normal macrophages. They then moved to living experiments using mice genetically engineered to develop atherosclerosis when fed a high-fat diet. Finally, they tested the probe on blood serum samples from human patients with varying degrees of arterial narrowing to see if it could detect disease severity.
The probe works by changing color and glowing brighter in the near-infrared region of light when LAP is present, creating a measurable signal that correlates with the amount of protein present.
This research approach is important because current methods for diagnosing atherosclerosis often require expensive imaging tests like CT scans or ultrasounds. A simple blood test using this probe could potentially identify at-risk patients much earlier and more affordably, allowing for preventive treatment before serious complications occur.
The study demonstrates a clear progression from laboratory experiments to animal models to human samples, which is a solid scientific approach. The probe showed low toxicity with no organ damage observed, suggesting safety for potential clinical use. However, the study doesn’t specify exact sample sizes for human testing, and this is still a proof-of-concept study rather than a large-scale clinical trial, so more research is needed before clinical adoption.
What the Results Show
The LAP probe successfully distinguished foam cells (disease cells) from normal macrophages in laboratory settings, glowing much brighter when LAP was present. In living mice with atherosclerosis, the probe enabled clear imaging of atherosclerotic plaques, showing that it could visualize disease in a living organism.
When tested on human blood samples, the probe detected significantly elevated LAP activity in patients with atherosclerosis compared to controls. Most importantly, LAP levels were particularly high in patients with severe arterial stenosis (narrowing exceeding 60%), suggesting the probe could help identify the most at-risk patients.
The relationship between LAP levels and disease severity was strong and linear, meaning higher protein levels consistently corresponded with more advanced disease. This predictable relationship is crucial for a diagnostic tool because it means doctors could use the measurement to assess not just whether disease is present, but how severe it is.
The probe exhibited excellent safety characteristics with low toxicity and no observable damage to organs in the animal studies. The fluorescence response was rapid and specific to LAP, meaning it didn’t produce false signals from other proteins. The probe’s ability to work in the near-infrared region of light is advantageous because this wavelength penetrates tissue better than visible light, potentially allowing for better imaging in living patients.
This research builds on existing knowledge that LAP activity is elevated in atherosclerosis by creating the first fluorescent probe specifically designed to detect and measure this protein. Previous diagnostic approaches relied on imaging plaques directly or measuring general inflammation markers. This targeted approach is more specific and potentially more sensitive, offering a new angle for early disease detection that complements existing diagnostic methods.
The study doesn’t provide specific numbers for human patient samples tested, making it difficult to assess the statistical power of the human findings. This is still a proof-of-concept study, meaning it demonstrates the concept works but hasn’t yet been tested in large-scale clinical trials. The mouse model, while useful, doesn’t perfectly replicate human atherosclerosis. Additionally, the study doesn’t compare the probe’s performance to existing diagnostic methods, so we don’t yet know if it’s better than current approaches. Finally, the probe is still in development and would require significant additional testing and regulatory approval before becoming available for clinical use.
The Bottom Line
This research is promising but preliminary. It suggests that LAP measurement via fluorescent probe could become a useful diagnostic tool for atherosclerosis, but it’s not yet ready for clinical use. Current recommendations remain unchanged: follow your doctor’s advice regarding heart disease screening based on your age, risk factors, and family history. If this technology advances through clinical trials, it may eventually complement or improve upon existing diagnostic methods.
This research is most relevant to cardiologists, researchers developing new diagnostic tools, and people at risk for heart disease. It’s particularly interesting for individuals with family histories of early heart disease, those with multiple risk factors (smoking, high cholesterol, diabetes), or those over 40 without recent cardiovascular screening. However, until this moves through clinical trials, it remains a research finding rather than a practical tool for patients.
This is early-stage research. Typically, a promising diagnostic tool like this would require 5-10 years of additional development, clinical trials, and regulatory approval before becoming available in hospitals and clinics. Don’t expect this specific probe to be available soon, but it represents the type of innovation that could improve heart disease detection in the coming decade.
Frequently Asked Questions
Can this new probe detect heart disease earlier than current tests?
The probe shows promise for earlier detection by measuring LAP protein levels in blood, which correlate with atherosclerosis severity. However, it’s still in development and hasn’t been directly compared to existing diagnostic methods in clinical trials, so we can’t yet confirm it’s better than current approaches.
When will this LAP blood test be available to patients?
This is early-stage research. The probe would typically require 5-10 years of additional clinical trials and regulatory approval before becoming available in hospitals. It’s not yet ready for routine clinical use, though it represents promising future technology.
What does LAP protein have to do with heart disease?
LAP is an enzyme produced in higher amounts during atherosclerosis, the buildup of plaque in arteries. By measuring LAP levels, doctors could potentially assess both whether atherosclerosis is present and how severe it is, helping identify at-risk patients earlier.
Is this probe safe to use in patients?
Animal studies showed the probe has low toxicity with no organ damage observed. However, it hasn’t yet been tested in human clinical trials, so long-term safety in patients remains to be established before clinical approval.
How accurate is this probe compared to ultrasound or CT scans?
The study doesn’t directly compare the probe to existing imaging methods. While the probe showed strong correlation with disease severity in tested samples, its accuracy relative to current diagnostic standards hasn’t yet been established in clinical trials.
Want to Apply This Research?
- Once this technology becomes clinically available, users could track LAP levels from periodic blood tests alongside traditional cardiovascular risk factors (cholesterol, blood pressure, weight) to monitor their atherosclerosis risk trajectory over time.
- While waiting for this diagnostic tool to develop, users can track and improve modifiable risk factors: daily steps walked, weekly servings of heart-healthy foods, smoking status, and stress levels. These behaviors directly influence LAP levels and atherosclerosis progression.
- Establish a baseline cardiovascular health profile including current screening results, then monitor lifestyle changes quarterly. Once LAP testing becomes available, integrate periodic LAP measurements into annual cardiovascular health reviews to track disease progression or improvement.
This research describes a promising experimental diagnostic tool still in development. The LAP fluorescent probe is not yet approved for clinical use and is not available for patient testing. This article is for educational purposes only and should not be used for self-diagnosis. If you have concerns about heart disease risk or atherosclerosis, consult with a qualified healthcare provider about appropriate screening and diagnostic methods currently available. Do not delay seeking medical care based on this research. Always follow your doctor’s recommendations for cardiovascular health assessment and management.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.